ABSTRACT. Rationale: Mesenchymal stem cells secrete paracrine factors that can regulate lung permeability and decrease inflammation, making it a potentially attractive therapy for acute lung injury. However, concerns exist whether mesenchymal stem cells' immunomodulatory properties may have detrimental effects if targeted toward infectious etiologies of lung injury.
INTRODUCTION
Despite extensive research into the pathogenesis of acute lung injury and the acute respiratory distress syndrome (ALI/ARDS), mortality remains high [1] [2] [3] . Current treatment is supportive with lung protective ventilation and a fluid conservative strategy [4, 5] . Innovative therapies are needed. Recent studies have suggested that mesenchymal stem or stromal cells (MSCs) may have therapeutic applications in multiple models of lung disease [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Despite initial interest in their multi-potent properties, engraftment in the lung does not appear to play a major therapeutic role. The beneficial effect of MSCs derives from their capacity to secrete paracrine factors that modulate immune responses and alter the responses of the endothelium or epithelium and inflammatory cells to injury [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Because of the immunosuppressive properties of MSCs, one safety concern is a potential deleterious effect on host defense against bacterial infection.
Bacterial pneumonia and sepsis from a non-pulmonary cause are the two most common etiologies of ALI/ARDS [2] . However, recent studies in mice have provided evidence for the beneficial effects of MSCs in the treatment of sepsis [17, 29] , although the mechanism for enhanced bacterial clearance was not clearly identified.
In the first part of this study, we hypothesized that clinical grade, cryopreserved bone marrow derived human allogeneic MSCs from a Good Manufacturing Practice facility would be as effective in restoring alveolar fluid clearance (AFC) as human MSCs cultured in vitro in our ex vivo perfused human lung injured with E.coli endotoxin. These clinical grade human MSCs were thawed and infused as they would be in a clinical trial. Clinical grade MSCs restored AFC rate to a normal level and decreased inflammation following endotoxin-induced ALI with similar efficacy as cultured human MSCs [30] .
In the second part of these studies, we hypothesized that these same clinical grade human MSCs would be effective in an infectious model of lung injury, E.coli pneumonia. Intrabronchial instillation of live E.coli bacteria resulted in a marked decrease in AFC and an intense pro-inflammatory response. Human MSCs administration following E.coli pneumonia-induced lung injury fully restored AFC, decreased inflammation and reduced total bacterial load in the injured alveolus. During the period of this study, Wu et al. reported in a mice pneumonia model that keratinocyte growth factor (KGF) stimulated the secretion of GM-CSF by alveolar epithelial cells, which activated alveolar macrophages by STAT5 phosphorylation and increased the phagocytosis and killing of Gram-negative bacteria [31] . Previously, we reported that MSCs secreted KGF and was an important paracrine mechanism through which MSCs restored vectorial ion and fluid transport in injured human alveolar epithelial type II cells [30] . To determine if KGF secretion by MSCs was involved in bacterial killing, we conducted studies with MSCs or KGF in the ex vivo perfused human lung and isolated blood monocytes exposed to E.coli bacteria.
MATERIALS AND METHODS

Ex Vivo Perfused Human Lung and In Vitro Monocyte Studies.
A detailed description of the ex vivo perfused human lung as previously published [30] and blood monocytes grown in vitro injured with E.coli bacteria as well as the measurement of various parameters such as AFC, percent phagocytosis of alveolar macrophages and total neutrophil and bacterial CFU counts in the alveolar fluid or conditioned medium can be found in the Online Data Supplement. All other techniques and reagents used are standard.
Data Analysis Plan.
Results were expressed as the mean  SD if the data was normally distributed. Comparisons between two groups were made using the unpaired t-test.
Comparisons with a sample over time were made by repeated measures of analysis of variance (ANOVA) using the Bonferroni correction for multiple-comparison testing using Statview (SAS Institute Inc.). 
RESULTS
Clinical Grade Human
Effect of Human Mesenchymal Stem Cells on Alveolar Fluid Clearance and Inflammatory
Cell Infiltration into the Injured Lung Following E.coli Pneumonia. Instillation of 10 9 colony forming units (CFU) of E.coli markedly impaired AFC by 80%, increased the influx of neutrophils into the injured alveolus, and was associated histologically with inflammatory cells influx, thickening of the interstitium and hemorrhage at 6 h. Instillation of 5 x 10 6 human MSCs IB or IV 1 h following E.coli induced lung injury restored AFC rate to a normal level (Figure 2A 
Effect of Human Mesenchymal Stem Cells on Alveolar Bacterial Load Following E.coli
Pneumonia. Instillation human MSCs IB or IV 1 h following E.coli pneumonia significantly reduced the bacterial load at 6 h in the injured alveolus ( Figure 3A) . Instillation of NHLF had no effect. Doubling the dose of MSCs to 10 x 10 6 cells IV decreased the bacterial load by an additional 40% from E.coli pneumonia, suggesting a dose response. To determine if MSCs secreted anti-microbial peptides/proteins into the injured alveolus, we removed cells and bacteria from the alveolar fluid of lungs exposed to E.coli with and without MSCs therapy and reexposed this alveolar conditioned medium to E.coli in vitro. Alveolar fluid from lungs treated with MSCs had increased anti-microbial activity compared to the lungs exposed to E.coli alone (Figure 3B) . Doubling the dose of MSCs to 10 x 10 6 cells IV to E.coli injured human lungs further increased the anti-microbial activity of the alveolar fluid.
Effect of Human Mesenchymal Stem Cells on Alveolar Macrophage Phagocytosis of E.coli
Bacteria. In addition to the anti-microbial factors secreted by MSCs [32, 33] , recent evidence showed that MSCs could increase bacterial clearance by enhancing monocyte phagocytosis [29] . Therefore, we tested the effect of MSCs on alveolar macrophage phagocytosis in the human lung injured with E.coli. Although there was no significant difference in total alveolar macrophage counts, instillation of human MSCs IB 1 h following E.coli pneumonia significantly increased the phagocytosis % and index of alveolar macrophages against E.coli bacteria at 6 h. Although not statistically significant, instillation of human MSCs IV 1 h following E.coli pneumonia also increased the phagocytosis % and index of alveolar macrophages against E.coli bacteria by 80% and 110% respectively at 6 h. (Figure 4) . (Figure 5A-D) . In separate experiments, to determine the effect of antibiotics alone, we administered 0.2 gm ampicillin into the perfusate at 1 h. The antibiotic treatment restored most of the parameters of lung injury, but there was no effect on AFC. However, the addition of IB MSCs at 2 h following IV ampicillin at 1 h significantly restored AFC and had an additive effect in reducing the total bacterial load in both the injured alveolus and the perfusate following the induction of the pneumonia. reported the protective effect of adipose tissue-derived human and mouse MSCs in mouse experimental colitis and sepsis, which was associated with improved bacterial clearance [34] .
Effect of Human Mesenchymal
However, the actual mechanisms underlying enhanced bacterial clearance were not clearly identified.
Macrophages and monocytes play an important role in the production of inflammatory mediators during sepsis, and they appear to be a major cell target in the protective effect of MSCs. Mei et al. reported that the improvement in bacterial clearance in syngeneic MSCs treated septic mice could be in part explained by enhanced phagocytic activity of splenic monocytes [29] ; these authors demonstrated enhancement of phagocytosis in the CD11+ cell population isolated from mouse spleen after MSCs treatment. Kim and Hematti [35] reported that human MSCs improved phagocytic activity of monocyte-derived macrophages when co-cultured in vitro. They reported that co-culture of human MSCs and macrophages induced an alternative state (M2) of macrophage activation, which is characterized by anti-inflammatory properties and more potent phagocytic activity. In a mouse model of peritoneal sepsis induced by Gram negative bacteria, we recently found that blood monocytes isolated from mice treated with MSC showed increased phagocytic activity compared to monocytes from control groups [36] . We also demonstrated that MSCs can inhibit bacterial growth directly in part through the secretion of antimicrobial peptide/proteins, such as LL-37 and Lipocalin-2 [32, 33] . More recently, several investigators found that MSCs have Toll-like and formyl peptide-like receptors and become activated in response to different bacterial products, suggesting that MSCs may be directly involved in innate immune response [13, 37] .
In this study, we identified several mechanisms underlying the anti-microbial effect of MSCs, primarily dependent on the secretion of KGF. KGF is a potent epithelial specific mitogen and differentiation factor that plays a central role in development and repair of injured epithelial tissues [38] . KGF is produced exclusively by mesenchymal cells and act on epithelial cells through the alternatively spliced FGF-2 tyrosine kinase receptor, FGFR2-IIIb. Recombinant KGF pretreatment reduced mortality following intra-tracheal instillation of hydrochloric acid [39, 40] , bleomycin [41, 42] , hyperoxia [43, 44] and Pseudomonas aeruginosa [45] . microvesicles that the epithelium engulfed, which restored alveolar ATP levels and reduced lung injury [46] . The contribution of cell-mediated effects on both the alveolar epithelium and macrophages to understand the net therapeutic activity of MSC will need to be further studied to determine if MSCs are more potent than the individual secreted peptides/proteins, such as KGF. There was no statistical difference in the absolute alveolar macrophage counts between groups.
(C) Human lungs exposed to E.coli bacteria with and without MSCs were fixed in 10% formalin at 6 h. Sections were stained with hematoxylin and eosin. The administration of human MSCs 1 h after E.coli pneumonia injury reduced the level of hemorrhage, edema and cellularity in the injured lung lobe at 6 h. control CFU counts/ml and  P<0.05 vs. KGF CFU counts/ml. 
